Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

ZeptoMetrix™ releases new SARS-CoV-2 Coronavirus Quality Control

ZeptoMetrix™ newly inactivated and non-infectious NATtrol™ SARS-CoV-2 Recombinant (0831402) is available for laboratory quality control and test validation.


News provided by

ZeptoMetrix Corporation

Mar 11, 2020, 01:00 ET

Share this article

Share toX

Share this article

Share toX

SARS-CoV-2
SARS-CoV-2

BUFFALO, N.Y., March 11, 2020 /PRNewswire-PRWeb/ -- In response to the current COVID-19 global health emergency, ZeptoMetrix™ Corporation (ZMC) announced today the development and release of a SARS-CoV-2 recombinant construct - NATtrol™ SARS-CoV-2 (recombinant) Stock - 0831042.

This non-infectious quality control incorporates a recombinant construct associated with targeted detection regions of the virus which may be utilized in the development of molecular assays designed to detect SARS-CoV-2 as well as safely utilized in BSL-2 facilities in place of the live virus, as non-infectious, external quality controls for assays developed to detect SARS-CoV-2.

"At present, it is critical for ZeptoMetrix to be able to quickly provide a commercial solution for a non-infectious SARS-CoV-2 quality control for safe use by diagnostic test developers." - Shawn R. Smith, President, ZeptoMetrix

Post this

As the health risk posed by COVID-19 sees prolific daily growth, the CDC recommendations for infection prevention and control is evolving quickly. As with Zika, MERS, H1N1, and SARS, ZeptoMetrix is uniquely positioned to assist its partners and customers with an array of quality controls, research reagents, developmental tools and scientific expertise during our present emergency.

It is imperative for overall public health that our ID community better understand SARS-CoV-2. ZeptoMetrix has made it a priority to provide clinical laboratories, assay developers, manufacturers, researchers and healthcare workers alike with equal access to its extensive collection of coronavirus products.

"As we've learned, you always need the right tools for the right job" explains Shawn R. Smith, President of ZeptoMetrix, "…and our comprehensive availability of off-the-shelf coronavirus products helps provide the Infectious Disease diagnostics community with as many precise and dependable tools as possible. At present, it is critical for ZeptoMetrix to be able to quickly provide a commercial solution for a non-infectious SARS-CoV-2 quality control for safe use by diagnostic test developers."

"In conjunction with our existing and ever growing product listing, I am proud in our Team's ability to meet today's challenges and positively impact public health efforts in any manner we can."

ZeptoMetrix is presently in production of additional SARS-CoV-2 research materials and controls to assist in the rapid development of diagnostic tests and provide safe options for intact, non-infectious QC materials. Please visit our website and review upcoming press releases with regards to SARS-CoV-2 Lysate, SARS-CoV-2 Heat Inactivated Culture Fluid and NATtrol™ SARS-CoV-2.

ZEPTOMETRIX CORONAVIRUS PRODUCTS:
Coronavirus 229E
NATtrol™ Coronavirus 229E Stock - NATCOV(299E)-ST    
Coronavirus Strain: 229E Culture Fluid - 0810229CF
Coronavirus Strain: 229E Heat Inactivated Culture Fluid - 0810229CFHI
Coronavirus Strain: 229E Lysate - 0810229

Coronavirus NL63
NATtrol™ Coronavirus NL63 Stock - NATCOV(NL63)-ST
Coronavirus Strain: NL63 Culture Fluid - 0810228CF
Coronavirus Strain: NL63 Heat Inactivated Culture Fluid - 0810228CFHI
Coronavirus Strain: NL63 Lysate - 0810228

Coronavirus OC43
NATtrol™ Coronavirus OC43 Stock - NATCOV(OC43)-ST
Coronavirus Strain: OC43 Culture Fluid - 0810024CF
Coronavirus Strain: OC43 Heat Inactivated Culture Fluid - 0810024CFHI
Coronavirus Strain: OC43 Lysate - 0810024

MERS-CoV Florida/USA-2_Saudi Arabia_2014
NATtrol™ MERS-CoV Stock - NATMERS-ST
MERS-CoV Strain: Florida/USA-2_Saudi Arabia_2014 Culture Fluid - 0810575CF
MERS-CoV Strain: Florida/USA-2_Saudi Arabia_2014 Heat Inactivated Culture Fluid - 0810575CFHI

SARS 2003-00592
NATtrol™ Coronavirus SARS Stock - NATSARS-ST

SARS-CoV-2 Recombinant                        
NATtrol SARS-CoV-2 (recombinant) Stock - 0831042

About ZeptoMetrix™
ZeptoMetrix Corporation (ZMC) is an established industry leader in the design, development, and delivery of innovative, quality solutions to the Infectious Disease Diagnostics Market. Our expertise and abilities in Molecular Diagnostics, including External Quality Controls, Verification Panels, Proficiency Panels, Customized and OEM Products/Services have set the industry standard for performance and reliability and made ZeptoMetrix the preferred choice for independent 3rd party QC materials.

Founded in 1999, ZeptoMetrix is headquartered in Buffalo, NY with additional facilities in Franklin, Massachusetts.

About NATtrol™
Globally, millions of people are tested for infectious diseases each year. The implications of reporting either a false positive or a false negative can be devastating to the patient. Accurate and sensitive diagnostics are necessary to confirm that laboratories are providing patients with proper testing results. Utilizing ZeptoMetrix NATtrol QC materials on a consistent basis helps to monitor testing performance and enhance confidence in testing results.

ZeptoMetrix NATtrol Molecular Diagnostics products are an essential component of today's ever-evolving testing market and are designed to provide safe, accurate and cost-effective support for activities relating to the analysis and identification of possible disease-causing microorganisms. The patented ZeptoMetrix NATtrol process renders highly-purified microorganisms non-infectious while allowing internal nucleic acids to remain intact, thereby serving as an ideal reference material for molecular diagnostic testing applications. Representing a total process control, from DNA extraction through amplification and eventual detection, NATtrol products are ready-to-use, refrigerator stable, and safe for operators to handle.

The routine and repetitive use of NATtrol™ External Run Controls and Verification Panels help enable laboratories to monitor performance and identify trends in daily test variations, test kit lot changes, and among individual operators.
For Sales and/or information regarding ZeptoMetrix, NATtrol Molecular Quality Controls & Panels, and Development/Custom Services, please contact ZeptoMetrix Customer Service.

Contact:
ZeptoMetrix Corporation, Customer Service
878 Main Street
Buffalo, NY 14202
716-882-0920
custserv(at)zeptometrix(dot)com
http://www.zeptometrix.com

Media:
Michael Hershfield, Vice President, Sales & Marketing                            
508-553-5852
[email protected]

SOURCE ZeptoMetrix Corporation

Related Links

http://www.zeptometrix.com

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.